Abstract
Prof Marcus Maurer opened the symposium with an introduction to chronic urticaria (CU), as well as its two subtypes (chronic spontaneous urticaria [CSU] and chronic inducible urticaria [CIndU]), and the currently available therapeutic strategies. Dr Clive Grattan spoke about the burden of disease in patients with CSU and the specific effects it has on a patient’s quality of life as well as the socioeconomic impact. Dr Donald Stull explained the importance of measuring the impact of disease using patient reported outcomes. Prof Ana Giménez-Arnau concluded the symposium by presenting the latest data on omalizumab for refractory CSU while touching on the recommendations in the latest urticaria guidelines. Interactive keypads were available throughout the symposium which allowed delegates to vote on different questions about their experience in treating patients with urticaria, posed by the speakers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
